Irreversible Airway Obstruction Assessed by High-resolution Computed Tomography (HRCT), Exhaled Nitric Oxide (FENO), and Biological Markers in Induced Sputum in Patients with Asthma

Overview

Journal Wien Klin Wochenschr

Publisher Springer

Specialty General Medicine

Date 2014 Aug 21

PMID 25138548

Citations 2

Authors

Lanlan Zhang

Jin Gang

Cao Zhigang

Cui Yali

Shen Baozhong

Zhang Fangbiao

Chuntao Liu

Affiliations

Soon will be listed here.

Abstract

Objective: The objective of this study was to explore the significance of assessing irreversible airway obstruction (IAO) in asthma patients by high-resolution computed tomography (HRCT), biological markers in induced sputum, and exhaled nitric oxide (FENO).

Methods: The study was conducted in 34 patients with IAO, 46 patients with reversible airway obstruction (RAO), 40 patients who did not have airway obstruction (NAO), and 40 healthy subjects serving as controls. These patients received a step therapy for at least 3 months based on the guidelines for the prevention and treatment of asthma. After achieving complete or partial control of asthma, HRCT, lung function, FENO, and chemokine levels in induced sputum were measured.

Results: The airway wall area (WA; %) correlated with forced expiratory volume-1 (FEV-1(L); r = -0.67, p < 0.0001), and significant differences in bronchial wall thickening (BWT) of the LEVEL E generation airways were observed between the asthma and control groups (p < 0.01). FENO levels correlated with FEV-1 (%) in the IAO group (r = 0.49, p = 0.01). The levels of matrix metalloproteases-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in asthma patients with IAO, RAO, and NAO were significantly higher than those in the controls (p < 0.05). The level of neutrophilia in the sputum from the IAO group was higher than that from the RAO, NAO and control groups.

Conclusion: Asthma patients with IAO have an increased BWT. Airway measurements with HRCT scans appear to be valuable in the evaluation of airway remodeling in asthma patients with IAO.

Citing Articles

Chinese expert consensus on diagnosis and management of severe asthma.

Lin J, Yang D, Huang M, Zhang Y, Chen P, Cai S J Thorac Dis. 2019; 10(12):7020-7044.

PMID: 30746249 PMC: 6344700. DOI: 10.21037/jtd.2018.11.135.

The Association of Gum Bleeding with Respiratory Health in a Population Based Study from Northern Europe.

Real F, Perez Barrionuevo L, Franklin K, Lindberg E, Bertelsen R, Benediktsdottir B PLoS One. 2016; 11(1):e0147518.

PMID: 26808490 PMC: 4725728. DOI: 10.1371/journal.pone.0147518.

References

Deykin A, Massaro A, Drazen J, Israel E . Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. Am J Respir Crit Care Med. 2002; 165(12):1597-601. DOI: 10.1164/rccm.2201081. View

. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003; 22(3):470-7. DOI: 10.1183/09031936.03.00261903. View

. Recommendations for standardized procedures for the on-line and off-line measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children-1999. This official statement of the American Thoracic Society was adopted.... Am J Respir Crit Care Med. 1999; 160(6):2104-17. DOI: 10.1164/ajrccm.160.6.ats8-99. View

Berrington de Gonzalez A, Darby S . Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet. 2004; 363(9406):345-51. DOI: 10.1016/S0140-6736(04)15433-0. View

Bernstein J, Davis B, Alvarez-Puebla M, Nguyen D, Levin L, Olaguibel J . Is exhaled nitric oxide a useful adjunctive test for assessing asthma?. J Asthma. 2009; 46(9):955-60. DOI: 10.3109/02770900903265804. View

Woo S, Lee J, Kim H, Kang J, Sun Y, Hahn Y . Utility of fractional exhaled nitric oxide (F(E)NO) measurements in diagnosing asthma. Respir Med. 2012; 106(8):1103-9. DOI: 10.1016/j.rmed.2012.03.022. View

Dupont L, Demedts M, Verleden G . Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest. 2003; 123(3):751-6. DOI: 10.1378/chest.123.3.751. View

Elkington P, OKane C, Friedland J . The paradox of matrix metalloproteinases in infectious disease. Clin Exp Immunol. 2005; 142(1):12-20. PMC: 1809491. DOI: 10.1111/j.1365-2249.2005.02840.x. View

Little S, Sproule M, Cowan M, MacLeod K, Robertson M, LOVE J . High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax. 2002; 57(3):247-53. PMC: 1746285. DOI: 10.1136/thorax.57.3.247. View

10.

Delgado-Corcoran C, Kissoon N, Murphy S, Duckworth L . Exhaled nitric oxide reflects asthma severity and asthma control. Pediatr Crit Care Med. 2003; 5(1):48-52. DOI: 10.1097/01.CCM.0000105310.00799.51. View

11.

Kharitonov S, Yates D, Robbins R, Shinebourne E, Barnes P . Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994; 343(8890):133-5. DOI: 10.1016/s0140-6736(94)90931-8. View

12.

Mattos W, Lim S, Russell R, Jatakanon A, Chung K, Barnes P . Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge, and inhaled corticosteroids. Chest. 2002; 122(5):1543-52. DOI: 10.1378/chest.122.5.1543. View

13.

Saglani S, Papaioannou G, Khoo L, Ujita M, Jeffery P, Owens C . Can HRCT be used as a marker of airway remodelling in children with difficult asthma?. Respir Res. 2006; 7:46. PMC: 1435892. DOI: 10.1186/1465-9921-7-46. View

14.

. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am Rev Respir Dis. 1987; 136(1):225-44. DOI: 10.1164/ajrccm/136.1.225. View

15.

Vignola A, Paganin F, Capieu L, Scichilone N, Bellia M, Maakel L . Airway remodelling assessed by sputum and high-resolution computed tomography in asthma and COPD. Eur Respir J. 2004; 24(6):910-7. DOI: 10.1183/09031936.04.00032603. View

16.

Moore W, Peters S . Severe asthma: an overview. J Allergy Clin Immunol. 2006; 117(3):487-94. DOI: 10.1016/j.jaci.2006.01.033. View

17.

Pavord I, Pizzichini M, Pizzichini E, Hargreave F . The use of induced sputum to investigate airway inflammation. Thorax. 1997; 52(6):498-501. PMC: 1758588. DOI: 10.1136/thx.52.6.498. View

18.

Hayakawa T . Tissue inhibitors of metalloproteinases and their cell growth-promoting activity. Cell Struct Funct. 1994; 19(3):109-14. DOI: 10.1247/csf.19.109. View

19.

Boulet L, Belanger M, Carrier G . Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. Am J Respir Crit Care Med. 1995; 152(3):865-71. DOI: 10.1164/ajrccm.152.3.7663797. View

20.

Roche W, Beasley R, Williams J, Holgate S . Subepithelial fibrosis in the bronchi of asthmatics. Lancet. 1989; 1(8637):520-4. DOI: 10.1016/s0140-6736(89)90067-6. View